Nabi Biopharmaceuticals - Product Pipeline Review - H2 2011

Nabi Biopharmaceuticals – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Nabi Biopharmaceuticals - Product Pipeline Review - H2 2011” provides data on the Nabi Biopharmaceuticals’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Nabi Biopharmaceuticals’s corporate website, SEC filings, investor presentations and featured press releases, both from Nabi Biopharmaceuticals and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Nabi Biopharmaceuticals - Brief Nabi Biopharmaceuticals overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Nabi Biopharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Nabi Biopharmaceuticals with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Nabi Biopharmaceuticals’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Nabi Biopharmaceuticals’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Nabi Biopharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Nabi Biopharmaceuticals’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Nabi Biopharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Nabi Biopharmaceuticals and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Nabi Biopharmaceuticals; Nabi Biopharmaceuticals - Key Therapeutics; Nabi Biopharmaceuticals - Pipeline Overview and Promising Molecules; Nabi Biopharmaceuticals - News; Nabi Biopharmaceuticals - Latest Updates; Nabi Biopharmaceuticals - Pipeline; Nabi Biopharmaceuticals - Discontinued/Dormant Projects SHOW LESS READ MORE >

List of Tables
List of Figures
Nabi Biopharmaceuticals Snapshot
Nabi Biopharmaceuticals Overview
Key Information
Key Facts
Nabi Biopharmaceuticals – Research and Development Overview
Key Therapeutic Areas
Nabi Biopharmaceuticals – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Nabi Biopharmaceuticals – Pipeline Products Glance
Nabi Biopharmaceuticals – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Nabi Biopharmaceuticals–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Nabi Biopharmaceuticals – Drug Profiles
EnteroVAX
Product Description
Mechanism of Action
R&D Progress
NicVAX
Product Description
Mechanism of Action
R&D Progress
S007A
Product Description
Mechanism of Action
R&D Progress
Nabi Biopharmaceuticals – Pipeline Analysis
Nabi Biopharmaceuticals – Pipeline Products by Therapeutic Class
Nabi Biopharmaceuticals – Pipeline Products by Route of Administration
Nabi Biopharmaceuticals – Pipeline Products by Molecule Type
Nabi Biopharmaceuticals – Recent Pipeline Updates
Nabi Biopharmaceuticals - Dormant Projects
Nabi Biopharmaceuticals – Company Statement
Nabi Biopharmaceuticals – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 29, 2008: Nabi Biopharmaceuticals Announces Successful Final Results Of NicVAX Immunogenicity Study
Sep 29, 2009: Nabi Biopharmaceuticals Receives Grant Supporting Further NicVAX Development
Feb 25, 2004: Nabi Biopharmaceuticals Announces Encouraging Results From NicVAX Phase I/II Clinical Trial In Smokers And Non-smokers
May 24, 2006: Nabi Biopharmaceuticals Initiates Phase IIB "Proof-Of-Concept" Study For NicVAX
Dec 23, 2008: Nabi Biopharmaceuticals Reaches Special Protocol Agreement With FDA For NicVAX Phase 3 Trial Protocol
Jul 20, 2005: Nabi Biopharmaceuticals Announces Completion Of NicVAX Phase II Clinical Trial Enrollment
Jul 18, 2011: Nabi Biopharmaceuticals Announces Results Of First NicVAX Phase III Clinical Trial
Mar 18, 2010: Nabi Initiates Second Phase III Study For NicVAX
Jul 14, 2010: Nabi Biopharmaceuticals Completes Enrollment In First NicVAX Phase III Clinical Trial
Sep 12, 2005: Nabi Biopharmaceuticals Receives NIDA Grant To Fund NicVAX Development
Nov 09, 2010: Nabi Completes Enrollment Of Second NicVAX Phase III Clinical Trial To Treat Nicotine Addiction And Prevent Smoking Relapse
Nov 07, 2007: Nabi Biopharmaceuticals Announces Successful Completion of NicVAX Phase 2b Trial
Jun 03, 2009: Nabi Biopharmaceuticals Receives Scientific Advice On NicVAX From The European Medicines Agency
Sep 01, 2010: Nabi Announces Long-Term Manufacturing Agreement With Diosynth RTP For NicVAX
Financial Deals Landscape
Nabi Biopharmaceuticals, Deals Summary
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Nabi Biopharmaceuticals Acquires Aloprim From DSM Pharmaceuticals
Partnerships
Nabi Biopharmaceuticals Enters Into Research Agreement With USU And The Henry M. Jackson Foundation
Nabi Biopharmaceuticals Enters Into Collaboration With National Institute Of Allergy And Infectious Diseases
Nabi Biopharmaceuticals Enters Into Co-Development Agreement With Kedrion
Nabi Biopharmaceuticals Enters Into Agreement With Kamada
AcroMetrix Signs An Agreement With Nabi Biopharmaceuticals
Licensing Agreements
Nabi Biopharmaceuticals Enters Into License Agreement With GlaxoSmithKline
Nabi Biopharmaceuticals Enters Into Agreement With ProMetic Life Sciences
Debt Offering
Nabi Biopharmaceuticals Issues 2.875% Convertible Senior Notes For $112.4 Million
Asset Transactions
GlaxoSmithKline Acquires PentaStaph And Related Assets From Nabi Biopharmaceuticals
Biotest Acquires Biologics Business Unit From Nabi Biopharmaceuticals
Bioniche Teoranta Acquires Aloprim From Nabi Biopharmaceuticals
Fresenius Medical Care Acquires Rights Of PhosLo From Nabi Biopharmaceuticals
AcroMetrix Acquires ViroSure Product Line From Nabi Biopharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Nabi Biopharmaceuticals – Pipeline by Therapy Area and Indication, H2 2011
Nabi Biopharmaceuticals – Pipeline by Stage of Development, H2 2011
Nabi Biopharmaceuticals – Monotherapy Products in Pipeline, H2 2011
Nabi Biopharmaceuticals – Phase III, H2 2011
Nabi Biopharmaceuticals - Pipeline By Therapeutic Class, H2 2011
Nabi Biopharmaceuticals – Pipeline By Route of Administration, H2 2011
Nabi Biopharmaceuticals – Pipeline By Molecule Type, H2 2011
Nabi Biopharmaceuticals – Recent Pipeline Updates, H2 2011
Nabi Biopharmaceuticals - Dormant Developmental Projects, 2010
Nabi Biopharmaceuticals, Other Locations
Nabi Biopharmaceuticals, Deals Summary
Nabi Biopharmaceuticals Acquires Aloprim From DSM Pharmaceuticals
Nabi Biopharmaceuticals Enters Into Research Agreement With USU And The Henry M. Jackson Foundation
Nabi Biopharmaceuticals Enters Into Collaboration With National Institute Of Allergy And Infectious Diseases
Nabi Biopharmaceuticals Enters Into Co-Development Agreement With Kedrion
Nabi Biopharmaceuticals Enters Into Agreement With Kamada
AcroMetrix Signs An Agreement With Nabi Biopharmaceuticals
Nabi Biopharmaceuticals Enters Into License Agreement With GlaxoSmithKline
Nabi Biopharmaceuticals Enters Into Agreement With ProMetic Life Sciences
Nabi Biopharmaceuticals Issues 2.875% Convertible Senior Notes For $112.4 Million
GlaxoSmithKline Acquires PentaStaph And Related Assets From Nabi Biopharmaceuticals
Biotest Acquires Biologics Business Unit From Nabi Biopharmaceuticals
Bioniche Teoranta Acquires Aloprim From Nabi Biopharmaceuticals
Fresenius Medical Care Acquires Rights Of PhosLo From Nabi Biopharmaceuticals
AcroMetrix Acquires ViroSure Product Line From Nabi Biopharmaceutical

List of Figures
Nabi Biopharmaceuticals – Pipeline by Therapy Area and Indication, H2 2011
Nabi Biopharmaceuticals – Pipeline by Stage of Development, H2 2011
Nabi Biopharmaceuticals – Monotherapy Products in Pipeline, H2 2011
Nabi Biopharmaceuticals – Pipeline By Therapeutic Class, H2 2011
Nabi Biopharmaceuticals – Pipeline By Molecule Type, H2 2011